EU health technology assessment authorities have set disclosure, oversight and accountability expectations for artificial intelligence used to prepare evidence for Joint Clinical Assessments.
Spain has established common referral, funding and follow-up arrangements intended to improve equity of access for patients who need high-complexity pharmaceutical treatment in another autonomous community.
AIFA’s first detailed analysis under its unified assessment structure shows a four-month average to the Commission or Board stage, rising to around nine months before legal publication for procedures other than generics.
A new public-statistics study uses official reimbursement and rebate data to show how high-cost hospital-linked medicines are shaping French expenditure growth.
The Netherlands continues to secure large expenditure reductions through financial arrangements, but unresolved negotiations and late dossiers still delay access to high-cost medicines.
France’s pharmaceutical industry barometer places access delays alongside clinical research and production indicators in a wider assessment of national competitiveness.
The June HTACG meeting moved EU joint clinical assessment beyond first publication, with further reports endorsed, device selection started and two medicine assessments discontinued.
Spain’s third official access report shows a further reduction in the median time from EU authorisation to public financing, while the proportion of innovative medicines financed in Spain remains broadly stable.
Responses to the first published EU joint clinical assessment focus on comparator evidence, national use of the report, dossier burden and patient involvement.
Germany’s statutory health insurance stabilisation bill has moved into parliamentary review, keeping proposed patent-medicine pricing tools at the centre of the access debate.
Sweden’s government has asked its pricing and reimbursement body to examine whether changing willingness to pay could affect access to cost-effective medicines.
Portugal has revised the legal framework for health technology assessment, financing and monitoring, aligning SiNATS more closely with EU joint HTA processes.
Norway’s hospital procurement body has replaced its 2018 medicines strategy with a national category plan for specialist-health-service medicine purchasing.
Sweden’s pricing and reimbursement body has set the implementation date for new guidelines and binding application rules for medicine subsidy and pricing.
Slovakia’s medicines bill has moved to second reading, bringing exceptional reimbursement, categorisation and off-patent access into a single legislative reform.
